What Oryn Therapeutics, LLC does

Oryn Therapeutics is a privately held, clinical-stage biotechnology company developing Orynotides™, a proprietary class of engineered macrocyclic peptides designed to precisely modulate dysregulated immune networks in chronic inflammatory, autoimmune, and fibro-inflammatory diseases. The platform is built on the highly constrained macrocyclic architecture of the rhesus θ-defensin (RTD-1) and is differentiated from conventional immune-suppressive therapies by seeking to reprogram interconnected inflammatory networks through allosteric modulation, rather than blocking single cytokines or signaling pathways. A central technical claim is dual extracellular/intracellular target engagement via a single cell-permeable peptide, occupying what the company describes as a middle ground between small molecules and biologics, with potential applicability to targets historically deemed undruggable.

The company's pipeline comprises five disclosed programs spanning injectable and oral formulations. ORTD-1, a natural peptide tool compound, completed Phase 1b in rheumatoid arthritis patients, providing clinical proof-of-concept for the platform. Three next-generation programs are in development: ORYN1002 (weekly subcutaneous, IND-enabling), ORYN1003 (daily oral, IND-enabling), and ORYN1064 (daily oral, discovery). The next-generation candidates are stated to incorporate learnings from clinical dosing of ORTD-1 in healthy volunteers and RA patients. Corporate headquarters are listed at 750 North San Vicente Boulevard, Suite 800 West, West Hollywood, California (per office-locations and contact data; firmographics list Vacaville, which is inconsistent with all other sources and should be treated as lower-confidence). The company's founding year is listed as 2013 in firmographics but is not independently corroborated in source materials.

Oryn is pre-revenue with no commercial products, no disclosed pricing, and a business model that depends on future licensing, partnership economics, or commercialization rather than product sales today. The company has embedded itself in the Lilly Catalyze360 ecosystem through a Catalyze agreement with Lilly ExploR&D (June 2026) and participation in Lilly TuneLab (2025), a collaborative AI/ML drug discovery platform. Leadership was substantially rebuilt in June 2026: Guy Rosenthal, Ph.D. was appointed President & CEO; Paul Carrington, Ph.D. was appointed SVP of Discovery & Early Development; Paul Sekhri (former CEO of vTv Therapeutics, with prior senior roles at Novartis, Teva, Sanofi, ARIAD, and TPG Biotech) joined as Executive Chairman; and Nina Kjellson (General Partner at Canaan) joined the board. Scientific founder Prof. Michael Selsted continues as Interim CSO. Backed by lead investors Mark Armenante and Young Sohn, with Canaan on the board, the company is positioning for what appears to be a financing or platform-expansion inflection.

Name

Oryn Therapeutics, LLC

Legal name

Oryn Therapeutics

Website

https://oryntherapeutics.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Oryn Therapeutics is a clinical-stage biotechnology company developing Orynotides™, a proprietary class of engineered macrocyclic peptides designed to reprogram dysregulated immune networks in chronic inflammatory and autoimmune diseases via dual extracellular and intracellular target engagement.

Ownership category

akta.pro rank

Product category

Macrocyclic Peptide Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Macrocyclic peptide therapeutics
• Autoimmune disease treatments
• Inflammatory disease therapeutics
• Peptide drug discovery
• Immune reprogramming therapeutics

Headquarters

HQ city

Vacaville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels1 record

Core offering

Oryn Therapeutics is a clinical-stage biotechnology company developing Orynotides™, a proprietary class of engineered macrocyclic peptide therapeutics designed to precisely modulate dysregulated immune networks in inflammatory, autoimmune, and fibro-inflammatory diseases. The pipeline includes ORTD-1 (Phase 1b completed in rheumatoid arthritis), ORYN1002 (weekly subcutaneous), ORYN1003 (daily oral), and ORYN1064 (daily oral, discovery), offered through internal development and strategic collaborations such as the Lilly Catalyze360 ecosystem.

Product overview

Oryn Therapeutics is advancing the Orynotide™ macrocyclic peptide platform—a novel class of immune-reprogramming macrocyclic peptides that occupy the middle ground between small molecules and biologics. The platform is designed to engage both extracellular and intracellular targets to precisely modulate dysregulated immune networks. The company's pipeline includes five distinct programs: ORTD-1 (natural peptide tool compound with completed Phase 1b in RA patients), ORYN1002 (weekly subcutaneous formulation in IND-enabling stage), ORYN1003 (daily oral formulation in IND-enabling stage), and ORYN1064 (daily oral formulation in discovery stage). The next-generation programs incorporate learnings from clinical dosing of ORTD-1 in healthy volunteers and RA patients.

Differentiator

Problem solved

Functional benefit

Brands

• Orynotide™: A novel class of engineered macrocyclic peptide therapeutics designed to precisely modulate complex biological networks involved in inflammatory, autoimmune, and fibro-inflammatory diseases through immune reprogramming rather than immune suppression.

Products and services

• Orynotide™ Macrocyclic Peptide Platform
• ORTD-1
• ORYN1002
• ORYN1003
• ORYN1064

Quantifiable outcome

• Phase 1b clinical proof-of-concept completed with ORTD-1 in rheumatoid arthritis patients, validating the macrocyclic peptide platform approach

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Lilly ExploR&DcoreStrategic or Co-development Partner · 23 June 2026Oryn entered into a Catalyze agreement with Lilly ExploR&D to access scientific capabilities intended to help accelerate its macrocyclic peptide programs. This collaboration provides Oryn with access to Lilly's research and development capabilities as part of the Lilly Catalyze360 ecosystem supporting biotech innovation.
• Lilly TuneLabcoreTechnology or Integration · 1 January 2025Oryn joined Lilly TuneLab, a collaborative AI/ML drug discovery platform. This is part of Lilly Catalyze360, which supports biotech innovation by providing access to strategic capital, lab space, technology, and research and development capabilities.

Recent moves4 records

Expansion highlights5 records

Direct peers

• Bicycle Therapeutics: Bicycle Therapeutics develops bicyclic peptide conjugates (Bicycles) and is the closest publicly-traded analog to Oryn's macrocyclic peptide platform, pursuing immune/cancer targets with a constrained peptide architecture that mirrors Orynotides' positioning between small molecules and biologics.
• Protagonist Therapeutics: Protagonist is a peptide-based therapeutic platform with late-stage assets in autoimmune/inflammatory indications (e.g., Janssen-partnered programs). Same constrained peptide modality and same target therapeutic areas as Oryn.
• PeptiDream: PeptiDream operates a proprietary macrocyclic/constrained peptide discovery platform (PDPS) with multiple pharma partnerships, directly comparable to the Orynotide platform in modality and business model.
• Zealand Pharma: Zealand Pharma develops peptide therapeutics including wholly engineered peptides, with programs across metabolic and inflammatory disease. Comparable peptide-platform approach and small-molecule/peptide hybrid ambition.

Broad incumbents

• AbbVie: AbbVie is the dominant player in autoimmune disease with Humira/Skyrizi/Rinvoq defining the competitive standard in RA and related indications. As the incumbent Oryn's next-gen ORYN1002/1003 would compete against, it defines the bar to beat clinically.
• Bristol Myers Squibb: BMS markets Zeposia (S1P modulator), Sotyktu (TYK2 inhibitor), and multiple other autoimmune assets across RA, IBD, and psoriasis. Represents both a competitor and a potential acquirer for autoimmune-focused peptide platforms.
• Eli Lilly: Lilly markets Olumiant (JAK inhibitor) and Taltz in autoimmune disease and is also Oryn's strategic partner via the Catalyze360/TuneLab ecosystem. Likely acquirer profile for the Orynotide platform.
• Pfizer: Pfizer has a broad autoimmune franchise (Xeljanz, Cibinqo, Litfulo) and active interest in novel inflammatory modalities. Represents a realistic strategic acquirer for Oryn's pipeline.
• Sanofi: Sanofi markets Dupixent (the leading IL-4/13 biologic in autoimmune/atopic disease) and has deep interest in next-generation autoimmune modalities. Comparable incumbent with overlapping target indications.
• Regeneron: Regeneron is a major biologic innovator with deep autoimmune/inflammation pipeline (e.g., IL-33, BCMA programs) and the antibody-engineering expertise that defines the biologic benchmark Oryn's macrocyclic peptides aim to complement.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oryn Therapeutics, LLC